«ICDs and Pacemakers». Hypertrophic Cardiomyopathy Association. Αρχειοθετήθηκε από το πρωτότυπο στις 15 Νοεμβρίου 2016. Ανακτήθηκε στις 14 Νοεμβρίου 2016.
«Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine». Journal of the American College of Cardiology64 (1): 83–99. July 2014. doi:10.1016/j.jacc.2014.05.003. PMID24998133.
«American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines». Journal of the American College of Cardiology42 (9): 1687–713. November 2003. doi:10.1016/S0735-1097(03)00941-0. PMID14607462.
«Biochemical characterisation of Troponin C mutations causing hypertrophic and dilated cardiomyopathies». Journal of Muscle Research and Cell Motility35 (2): 161–78. April 2014. doi:10.1007/s10974-014-9382-0. PMID24744096.
«Progression of left ventricular hypertrophy and the angiotensin-converting enzyme gene polymorphism in hypertrophic cardiomyopathy». International Journal of Cardiology96 (2): 157–63. August 2004. doi:10.1016/j.ijcard.2004.05.003. PMID15314809.
«Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death». Lancet342 (8879): 1085–6. October 1993. doi:10.1016/0140-6736(93)92064-Z. PMID8105312.
«Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene». Circulation: Cardiovascular Genetics5 (1): 10–7. February 2012. doi:10.1161/CIRCGENETICS.111.959973. PMID22144547.
«Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals». Clinical Research in Cardiology107 (1): 30–41. January 2018. doi:10.1007/s00392-017-1155-5. PMID28840316.
«Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program». JAMA296 (13): 1593–601. October 2006. doi:10.1001/jama.296.13.1593. PMID17018804.
«Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations». Journal of the American College of Cardiology48 (12): 2518–23. December 2006. doi:10.1016/j.jacc.2006.08.036. PMID17174192.
«Current management of hypertrophic cardiomyopathy». Current Treatment Options in Cardiovascular Medicine10 (6): 496–504. December 2008. doi:10.1007/s11936-008-0042-9. PMID19026180.
«Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus». Circulation92 (9 Suppl): II122-7. November 1995. doi:10.1161/01.CIR.92.9.122. PMID7586394.
«Myectomy or alcohol septal ablation surgery and percutaneous intervention go another round». Journal of the American College of Cardiology49 (3): 358–60. January 2007. doi:10.1016/j.jacc.2006.10.029. PMID17239718.
«First Experience with Percutaneous Mitral Valve Plication as Primary Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy». Journal of the American College of Cardiology67 (24): 2811–8. June 2016. doi:10.1016/j.jacc.2016.03.587. PMID27311518.
«American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines». Journal of the American College of Cardiology42 (9): 1687–713. November 2003. doi:10.1016/S0735-1097(03)00941-0. PMID14607462.
«Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy». JAMA298 (4): 405–12. July 2007. doi:10.1001/jama.298.4.405. PMID17652294.
«The incidence of pediatric cardiomyopathy in two regions of the United States». The New England Journal of Medicine348 (17): 1647–55. April 2003. doi:10.1056/NEJMoa021715. PMID12711739.
«Comparison of auscultatory and echocardiographic findings in healthy adult cats». Journal of Veterinary Cardiology12 (3): 171–82. December 2010. doi:10.1016/j.jvc.2010.05.003. PMID21075067.
«Familial hypertrophic cardiomyopathy in maine coon cats: an animal model of human disease». Circulation99 (24): 3172–80. June 1999. doi:10.1161/01.CIR.99.24.3172. PMID10377082.
«A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathy». Human Molecular Genetics14 (23): 3587–93. December 2005. doi:10.1093/hmg/ddi386. PMID16236761.
«A substitution mutation in the myosin binding protein C gene in ragdoll hypertrophic cardiomyopathy». Genomics90 (2): 261–4. August 2007. doi:10.1016/j.ygeno.2007.04.007. PMID17521870.
«Echocardiographic assessment of left ventricular geometry and the mitral valve apparatus in cats with hypertrophic cardiomyopathy». Journal of Veterinary Cardiology12 (1): 1–16. April 2010. doi:10.1016/j.jvc.2009.09.004. PMID20185379.
«Screening for hypertrophic cardiomyopathy in cats». Journal of Veterinary Cardiology17 Suppl 1: S134-49. December 2015. doi:10.1016/j.jvc.2015.07.003. PMID26776573.
«Multicenter evaluation of plasma N-terminal probrain natriuretic peptide (NT-pro BNP) as a biochemical screening test for asymptomatic (occult) cardiomyopathy in cats». Journal of Veterinary Internal Medicine25 (5): 1010–6. September 2011. doi:10.1111/j.1939-1676.2011.00776.x. PMID21985136.
«Utility of measuring plasma N-terminal pro-brain natriuretic peptide in detecting hypertrophic cardiomyopathy and differentiating grades of severity in cats». Veterinary Clinical Pathology40 (2): 237–44. June 2011. doi:10.1111/j.1939-165X.2011.00305.x. PMID21434959.
«Multi-centered investigation of a point-of-care NT-proBNP ELISA assay to detect moderate to severe occult (pre-clinical) feline heart disease in cats referred for cardiac evaluation». Journal of Veterinary Cardiology16 (4): 245–55. December 2014. doi:10.1016/j.jvc.2014.09.002. PMID25456274.
«The effect of ramipril on left ventricular mass, myocardial fibrosis, diastolic function, and plasma neurohormones in Maine Coon cats with familial hypertrophic cardiomyopathy without heart failure». Journal of Veterinary Internal Medicine20 (5): 1093–105. 2006. doi:10.1111/j.1939-1676.2006.tb00707.x. PMID17063701.
«Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine». Journal of the American College of Cardiology64 (1): 83–99. July 2014. doi:10.1016/j.jacc.2014.05.003. PMID24998133.
«American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines». Journal of the American College of Cardiology42 (9): 1687–713. November 2003. doi:10.1016/S0735-1097(03)00941-0. PMID14607462.
«Biochemical characterisation of Troponin C mutations causing hypertrophic and dilated cardiomyopathies». Journal of Muscle Research and Cell Motility35 (2): 161–78. April 2014. doi:10.1007/s10974-014-9382-0. PMID24744096.
«Progression of left ventricular hypertrophy and the angiotensin-converting enzyme gene polymorphism in hypertrophic cardiomyopathy». International Journal of Cardiology96 (2): 157–63. August 2004. doi:10.1016/j.ijcard.2004.05.003. PMID15314809.
«Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death». Lancet342 (8879): 1085–6. October 1993. doi:10.1016/0140-6736(93)92064-Z. PMID8105312.
«Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene». Circulation: Cardiovascular Genetics5 (1): 10–7. February 2012. doi:10.1161/CIRCGENETICS.111.959973. PMID22144547.
«Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals». Clinical Research in Cardiology107 (1): 30–41. January 2018. doi:10.1007/s00392-017-1155-5. PMID28840316.
«Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program». JAMA296 (13): 1593–601. October 2006. doi:10.1001/jama.296.13.1593. PMID17018804.
«Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations». Journal of the American College of Cardiology48 (12): 2518–23. December 2006. doi:10.1016/j.jacc.2006.08.036. PMID17174192.
«Current management of hypertrophic cardiomyopathy». Current Treatment Options in Cardiovascular Medicine10 (6): 496–504. December 2008. doi:10.1007/s11936-008-0042-9. PMID19026180.
«Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus». Circulation92 (9 Suppl): II122-7. November 1995. doi:10.1161/01.CIR.92.9.122. PMID7586394.
«Myectomy or alcohol septal ablation surgery and percutaneous intervention go another round». Journal of the American College of Cardiology49 (3): 358–60. January 2007. doi:10.1016/j.jacc.2006.10.029. PMID17239718.
«First Experience with Percutaneous Mitral Valve Plication as Primary Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy». Journal of the American College of Cardiology67 (24): 2811–8. June 2016. doi:10.1016/j.jacc.2016.03.587. PMID27311518.
«American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines». Journal of the American College of Cardiology42 (9): 1687–713. November 2003. doi:10.1016/S0735-1097(03)00941-0. PMID14607462.
«Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy». JAMA298 (4): 405–12. July 2007. doi:10.1001/jama.298.4.405. PMID17652294.
«The incidence of pediatric cardiomyopathy in two regions of the United States». The New England Journal of Medicine348 (17): 1647–55. April 2003. doi:10.1056/NEJMoa021715. PMID12711739.
«Comparison of auscultatory and echocardiographic findings in healthy adult cats». Journal of Veterinary Cardiology12 (3): 171–82. December 2010. doi:10.1016/j.jvc.2010.05.003. PMID21075067.
«Familial hypertrophic cardiomyopathy in maine coon cats: an animal model of human disease». Circulation99 (24): 3172–80. June 1999. doi:10.1161/01.CIR.99.24.3172. PMID10377082.
«A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathy». Human Molecular Genetics14 (23): 3587–93. December 2005. doi:10.1093/hmg/ddi386. PMID16236761.
«A substitution mutation in the myosin binding protein C gene in ragdoll hypertrophic cardiomyopathy». Genomics90 (2): 261–4. August 2007. doi:10.1016/j.ygeno.2007.04.007. PMID17521870.
«Echocardiographic assessment of left ventricular geometry and the mitral valve apparatus in cats with hypertrophic cardiomyopathy». Journal of Veterinary Cardiology12 (1): 1–16. April 2010. doi:10.1016/j.jvc.2009.09.004. PMID20185379.
«Screening for hypertrophic cardiomyopathy in cats». Journal of Veterinary Cardiology17 Suppl 1: S134-49. December 2015. doi:10.1016/j.jvc.2015.07.003. PMID26776573.
«Multicenter evaluation of plasma N-terminal probrain natriuretic peptide (NT-pro BNP) as a biochemical screening test for asymptomatic (occult) cardiomyopathy in cats». Journal of Veterinary Internal Medicine25 (5): 1010–6. September 2011. doi:10.1111/j.1939-1676.2011.00776.x. PMID21985136.
«Utility of measuring plasma N-terminal pro-brain natriuretic peptide in detecting hypertrophic cardiomyopathy and differentiating grades of severity in cats». Veterinary Clinical Pathology40 (2): 237–44. June 2011. doi:10.1111/j.1939-165X.2011.00305.x. PMID21434959.
«Multi-centered investigation of a point-of-care NT-proBNP ELISA assay to detect moderate to severe occult (pre-clinical) feline heart disease in cats referred for cardiac evaluation». Journal of Veterinary Cardiology16 (4): 245–55. December 2014. doi:10.1016/j.jvc.2014.09.002. PMID25456274.
«The effect of ramipril on left ventricular mass, myocardial fibrosis, diastolic function, and plasma neurohormones in Maine Coon cats with familial hypertrophic cardiomyopathy without heart failure». Journal of Veterinary Internal Medicine20 (5): 1093–105. 2006. doi:10.1111/j.1939-1676.2006.tb00707.x. PMID17063701.
«ICDs and Pacemakers». Hypertrophic Cardiomyopathy Association. Αρχειοθετήθηκε από το πρωτότυπο στις 15 Νοεμβρίου 2016. Ανακτήθηκε στις 14 Νοεμβρίου 2016.